Skip to main content

Health

GSK PLC GSK View profile

FDA approves GSK's Nelkarmi for previously treated lung cancer

selective focus photography of anatomy lungs — Credit: Photo by Robina Weermeijer on Unsplash
Photo by Robina Weermeijer on Unsplash

The US Food and Drug Administration has granted accelerated approval to Nelkarmi, GSK's new targeted therapy for adults with a specific form of advanced lung cancer who have already received earlier treatments.

The drug is approved for patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received either alectinib as their only prior ALK inhibitor, or two or more ALK inhibitors plus platinum-based chemotherapy.

Approval came ahead of the FDA's original target date of 27 November 2026 and is backed by Breakthrough Therapy and Orphan Drug designations.

The decision rests on data from the phase I/II ALKOVE-1 trial, which enrolled 700 patients with ALK-positive solid tumours, with the primary efficacy analysis covering 222 previously treated NSCLC patients.

In patients who had received only alectinib as prior therapy, the overall response rate (ORR) was 49%, with responses lasting six months or more in 76% of responders and 12 months or more in 52%.

In the heavier pre-treated group, two or more prior ALK inhibitors plus chemotherapy, the ORR was 32%, with six-month and 12-month durability rates of 69% and 51%, respectively.

Among patients with measurable brain metastases at baseline, intracranial ORR was 55% in the alectinib-only group, including 25% complete responses, and 26% in those with two or more prior ALK inhibitors, including 11% complete responses.

The most common adverse reactions included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, oedema, and fatigue, with 5% of patients permanently discontinuing treatment.

Nelkarmi, acquired through GSK's purchase of Nuvalent, is GSK's second lung cancer approval of 2026, following the FDA's clearance of Jideytro (zidesamtinib) for ROS1-positive NSCLC in July.